Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

PipelineDigest_2024Q4_Article_MAR-152-010325.1

BERWYN, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today launched its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource for information on new, pending and upcoming specialty and rare disease drug launches, biosimilars and cell and gene therapies (CGTs). This complimentary quarterly publication provides stakeholders and decision-makers with crucial, timely updates to support the needs of the specialty drug market.

“Specialty pharmaceutical product approvals are advancing at an unprecedented rate, underscoring the increasing wave of innovation across the healthcare sector,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “As the demand for novel therapies to address rare and complex conditions continues to increase, the AscellaHealth Specialty & Rare Pipeline Digest becomes a crucial resource for industry leaders seeking reliable, actionable information that supports effective go-to-market strategic planning and successful product commercialization. Our goal is to collaborate with manufacturers, payers and providers to enhance the affordability and distribution of these transformative therapies.”

The Q4 data highlights sustained growth in key specialty sectors, marked by notable increases in SP drug approvals and biosimilar launches. These valuable insights provide decision-makers with the information, data and expertise needed to develop and execute successful market access strategies.

“Effective product management and informed decision-making rely on dependable industry insights and precise data,” says Dea Belazi, CEO, AscellaHealth. “By offering this complimentary digest, we reaffirm our commitment to supporting our industry partners and delivering meaningful value across the specialty pharmaceutical landscape."

This digital resource complements the findings outlined in AscellaHealth’s 2024 Specialty Pharmaceutical Review: Key Highlights and Industry Trends, highlighting the industry’s rapid advancement driven by breakthroughs in AI, machine learning and advanced data analytics. Looking ahead, AscellaHealth anticipates continued industry progress and the accelerated development of specialty therapies, leading to improved therapeutic outcomes for rare diseases and more focused patient-centered care.

Access the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6f4565fd-0b87-4d06-a1bf-2a364346df26

This press release was published by a CLEAR® Verified individual.


Media:

Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.